Across TCGA pan-cancer cohorts, OR4B1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR4B1 data layer compared with 10 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR4B1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR4B1 expression acts as an unfavorable survival marker.
STAD, BLCA, and SKCM are the cancer types where OR4B1 Mutation most reproducibly stratifies survival.